Recombinant Human B7-H3 Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human B7-H3 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated human T cells. The ED₅₀ for this effect is 3-12 μg/mL.
  Optimal dilutions should be determined by each laboratory for each application.
• Source: Mouse myeloma cell line, NS0-derived human B7-H3 protein
  

  Human B7-H3 (Leu29-Pro245) Accession # NP_079516	DIEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: NP_079516
• N-terminal Sequence: Leu29
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: CD276
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 50 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 70-80 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human B7-H3 Fc Chimera Protein, CF

• B7H3
• B7-H3
• B7H34Ig-B7-H3
• B7-H3B7 homolog 3
• CD276 antigen
• CD276 molecule
• CD276
• Costimulatory molecule

Background

Human B7 homolog 3 (B7-H3) is a member of the B7 family of immune proteins that provide signals for regulating immune responses (1‑3). Other family members include B7-1, B7-2, B7-H2, PD-L1 (B7-H1), and PD-L2. B7 proteins are immunoglobulin (Ig) superfamily members with extracellular Ig-V-like and Ig-C-like domains and short cytoplasmic domains. Among the family members, they share about 20-40% amino acid (aa) sequence identity. The cloned human B7-H3 cDNA encodes a 316 aa type I membrane precursor protein with a putative 28 aa signal peptide, a 217 aa extracellular region containing one V-like and one C-like Ig domain, a transmembrane region, and a 45 aa cytoplasmic domain. An isoform of human B7-H3 containing a four-Ig-like domain extracellular region has also been identified. Human B7-H3 is not expressed on resting B cells, T cells, monocytes or dendritic cells, but is induced on dendritic cells and monocytes by inflammatory cytokines. B7-H3 expression is also detected on various normal tissues and in some tumor cell lines. Human B7-H3 does not bind any known members of the CD28 family of immunoreceptors. However, B7-H3 has been shown to bind an unidentified counter-receptor on activated T cells to costimulate the proliferation of CD4⁺ or CD8⁺ T cells. B7-H3 has also been found to enhance the induction of primary cytotoxic T lymphocytes and stimulate IFN-gamma production (1-3).

1. Chapoval, A.I. et al. (2001) Nat. Immunol. 2:269.
2. Sharpe, A.H. and G.J. Freeman (2002) Nat. Rev. Immunol. 2:116.
3. Coyle, A. and J. Gutierrez-Ramos (2001) Nat. Immunol. 2:203.

Publications for B7-H3/CD276 (1027-B3)(10)

Publications using 1027-B3

• Sun, Y;Maggs, L;Panda, A;Wright, SJ;Cicerchia, AM;Jenney, A;Perricone, MD;Mills, CE;Cattaneo, G;Ventin, M;Chen, F;Rasmussen, MQ;Miranda, A;Revach, OY;Fang, J;Fu, A;Bowling, PJ;Sharova, T;Lawless, A;Sorger, PK;Bardeesy, N;Wang, X;Flaherty, KT;Boland, GM;Mehta, A;Sade-Feldman, M;Ferrone, CR;Jenkins, RW; TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids Cancer immunology research 2025-01-09 [PMID: 39785827] (Flow Cytometery, Human)
• Xu, JC;Chen, H;Xu, P;You, XR;Zhu, GC;Gao, F; Clinical significance of B7-H3 expression in circulating CD4+CD25high T cells, CD14+ monocytes, and plasma for the progression of HIV infection BMC infectious diseases 2023-07-10 [PMID: 37430239] (Bioassay, Human)
• H Li, EB Harrison, H Li, K Hirabayash, J Chen, QX Li, J Gunn, J Weiss, B Savoldo, JS Parker, CV Pecot, G Dotti, H Du Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration Nature Communications, 2022-04-20;13(1):2154. 2022-04-20 [PMID: 35443752] (Flow Cytometry, Human)
• AK Grosskopf, L Labanieh, DD Klysz, GA Roth, P Xu, O Adebowale, EC Gale, CK Jons, JH Klich, J Yan, CL Maikawa, S Correa, BS Ou, AI d'Aquino, JR Cochran, O Chaudhuri, CL Mackall, EA Appel Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors Science Advances, 2022-04-08;8(14):eabn8264. 2022-04-08 [PMID: 35394838] (Flow Cytometry, Human)
• CC Zebley, HA Abdelsamed, HE Ghoneim, S Alli, C Brown, D Haydar, T Mi, T Harris, MA McGargill, G Krenciute, B Youngblood Proinflammatory cytokines promote TET2-mediated DNA demethylation during CD8 T�cell effector differentiation Cell Reports, 2021-10-12;37(2):109796. 2021-10-12 [PMID: 34644568] (Bioassay, Human)
• Y Zhang, L He, A Sadagopan, T Ma, G Dotti, Y Wang, H Zheng, X Gao, D Wang, AB DeLeo, S Fan, R Sun, L Yu, L Zhang, G Wang, S Ferrone, X Wang Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells Molecular Cancer Therapeutics, 2021-03-01;20(3):577-588. 2021-03-01 [PMID: 33653946] (Flow Cytometry, Human)
• UM Vogl, L Öhler, M Rasic, JM Frischer, M Modak, J Stöckl Evaluation of Prognostic Immune Signatures in Patients with Breast, Colorectal and Pancreatic Cancer Receiving Chemotherapy Anticancer Res., 2017-04-01;37(4):1947-1955. 2017-04-01 [PMID: 28373465] (ELISA (Standard))
• BR Yoon, YH Chung, SJ Yoo, K Kawara, J Kim, IS Yoo, CG Park, SW Kang, WW Lee Preferential Induction of the T Cell Auxiliary Signaling Molecule B7-H3 on Synovial Monocytes in Rheumatoid Arthritis J. Biol. Chem, 2015-12-23;291(8):4048-57. 2015-12-23 [PMID: 26702052] (Bioassay, Human)
• Zhang G, Wang J, Kelly J B7-h3 augments the inflammatory response and is associated with human sepsis. J. Immunol., 2010-08-09;185(6):3677-84. 2010-08-09 [PMID: 20696859] (Flow Cytometry, Human)
• Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich BC, Blute ML, Kwon ED Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin. Cancer Res., 2008;14(16):5150-7. 2008 [PMID: 18694993] (Bioassay, Human)

Bioinformatics

• Gene Symbol: CD276
• Uniprot:
  • NP_079516()